1-十八烷基咪唑烷-2,4-二酮 | 85117-83-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 中文名称: 1-十八烷基咪唑烷-2,4-二酮
• 英文名称: 1-Octadecylimidazolidine-2,4-dione
• CAS: 85117-83-5
• 化学式: C₂₁H₄₀N₂O₂
• 分子量: 352.6
• InChiKey: SMCUEMZWAQLBET-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8
• 重原子数：
  25
• 可旋转键数：
  17
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  49.4
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Additive for heat-sensitive recording material, the recording material, and method for production of the recording material
  申请人：SHOWA DENKO KABUSHIKI KAISHA

  公开号：EP0373251A1

  公开（公告）日：1990-06-20

  A hydantoin compound of the formula: (wherein R stands for an alkyl group of 8 to 20 carbon atoms) increases the sensitivity of a color developing reaction of a heat-sensitive recording material and enhances the high-speed recording property of the recording material without sacrifice of the whiteness thereof. The heat-sensitive recording material containing the hydantoin compound is novel to the art.

  式中的一种海因化合物： (其中 R 代表 8 至 20 个碳原子的烷基）可提高热敏记录材料显色反应的灵敏度，并增强记录材料的高速记录性能，同时不影响其白度。含有海因化合物的热敏记录材料是本领域的新技术。
• Pharmaceutical composition containing a hydantoin derivative and use of said derivative
  申请人：NIPPON ZOKI PHARMACEUTICAL CO., LTD.

  公开号：EP0780125A2

  公开（公告）日：1997-06-25

  The present invention is directed to a pharmaceutical composition comprising a hydantoin derivative represented by the following formula (I) or a pharmaceutically acceptable salt thereof wherein each of R1 and R2, which may be the same or different, represents hydrogen, an alkyl group or a cycloalkyl group; and each of X and Y, which may be the same or different, represents hydrogen, hydroxyl group, an alkyl group or an alkoxy group, or X and Y together represent an oxo group, and a pharmaceutically acceptable carrier or diluent. The above mentioned hydantoin derivative has an action of eliminating the active oxygen and the free radicals. Accordingly, it is useful for preparing a pharmaceutical agent for treating a variety of diseases in which active oxygen and free radicals are participated such as myocardial infarction, reperfusion disturbance, autoimmune diseases, fibrosis, pulmonary diseases, dermatological diseases, arthropathy, side effects of anticancer agents, radiation diseases, septic shock, inflammatory diseases and cataract.

  本发明涉及一种药物组合物，该药物组合物包含下式（I）所代表的 hydantoin 衍生物或其药学上可接受的盐 其中R1和R2（可以相同或不同）各自代表氢、烷基或环烷基；X和Y（可以相同或不同）各自代表氢、羟基、烷基或烷氧基，或X和Y共同代表氧代基团，以及药学上可接受的载体或稀释剂。 上述海因衍生物具有消除活性氧和自由基的作用。因此，它可用于制备治疗各种参与活性氧和自由基的疾病的药剂，如心肌梗塞、再灌注障碍、自身免疫性疾病、纤维化、肺部疾病、皮肤病、关节病、抗癌剂副作用、放射病、脓毒性休克、炎症性疾病和白内障。
• Therapeutic agent for intractable vasculitis
  申请人：NIPPON ZOKI PHARMACEUTICAL CO., LTD.

  公开号：EP1018339A1

  公开（公告）日：2000-07-12

  The invention provides a therapeutic agent for intractable vasculitis containing a hydantoin derivative represented by the formula (I) or a pharmaceutically acceptable salt thereof as an effective ingredient: wherein R1 and R2, which may be the same or different, represent hydrogen, an alkyl group or a cycloalkyl group; and each of X and Y, which may be the same or different, represent hydrogen, a hydroxyl group, an alkyl group or an alkoxy group, or X and Y together represent an oxo group. These compounds significantly suppress the generation of arthritis and arteritis (cutaneous ulcer and auricular infarcted necrosis) which were naturally developed in model animals (MRL/lpr), and further significantly elongat the survival rate of MRL/lpr mice. Consequently, the compound of the invention having low toxicity and less side effects is very useful as a highly safe therapeutic agent for intractable vasculitis such as malignant rheumatoid arthritis.

  本发明提供了一种治疗难治性脉管炎的药物，其有效成分含有由式（I）代表的海因衍生物或其药学上可接受的盐： 其中R1和R2可以相同或不同，分别代表氢、烷基或环烷基；X和Y可以相同或不同，分别代表氢、羟基、烷基或烷氧基，或X和Y共同代表氧代基团。 这些化合物能明显抑制模型动物（MRL/lpr）自然产生的关节炎和动脉炎（皮肤溃疡和耳廓梗塞坏死），并进一步明显延长 MRL/lpr 小鼠的存活率。因此，本发明的化合物毒性低、副作用小，是一种非常有用的治疗顽固性血管炎（如恶性类风湿性关节炎）的高安全性药物。
• Use of a hydantoin derivative in a pharmaceutical composition against hypoalbuminaemia
  申请人：NIPPON ZOKI PHARMACEUTICAL CO., LTD.

  公开号：EP1243261A1

  公开（公告）日：2002-09-25

  Disclosed is the use of a hydantoin derivative of the formula (I) wherein R1 and R2 each independently is H, alkyl or cycloalkyl; and X and Y each independently is H, OH, alkyl or alkoxy, or X and Y together form an oxo group, or a pharmaceutically acceptable salt, hydrate or complex thereof, for the manufacture of a medicament effective in the treatment of hypoalbuminaemia.

  公开了一种式（I）的海因衍生物的用途 其中 R1 和 R2 各自独立地为 H、烷基或环烷基；X 和 Y 各自独立地为 H、OH、烷基或烷氧基，或 X 和 Y 共同形成一个氧代基团，或其药学上可接受的盐、水合物或络合物，用于制造对治疗低白蛋白血症有效的药物。
• CARCINOGENESIS INHIBITOR
  申请人：National Cancer Center

  公开号：EP3639821A1

  公开（公告）日：2020-04-22

  An object of the present invention is to provide a carcinogenesis inhibitor having no side effect and having an excellent effect by oral administration. A carcinogenesis inhibitor of the present invention containing a hydantoin derivative or a pharmaceutically acceptable salt thereof as an active ingredient shows an inhibiting action for polyp formation and for cell proliferation, and has no side effect and highly safe whereby it is very highly useful as a pharmaceutical agent and a food such as supplement which prevent the occurrence and progress of cancer, inhibits the recurrence and metastasis of cancer and further achieves the therapeutic effect.

  本发明的目的是提供一种口服无副作用且效果极佳的致癌物抑制剂。 本发明的一种致癌抑制剂含有一种海因衍生物或其药学上可接受的盐作为有效成分，对息肉的形成和细胞增殖有抑制作用，且无副作用，安全性高，因此作为药物制剂和食品（如保健品）非常有用，可以防止癌症的发生和发展，抑制癌症的复发和转移，并进一步达到治疗效果。